Voyager Therapeutics (VYGR) Receivables - Net (2022 - 2026)

Voyager Therapeutics (VYGR) has 5 years of Receivables - Net data on file, last reported at $1.5 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net fell 7.95% year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2026 stood at $1.5 million (down 7.95% YoY), and the FY2025 full-year result was $1.8 million, up 19.68% from the prior year.
• Receivables - Net declined to $1.5 million in Q1 2026, from $1.8 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $80.1 million in Q4 2023 to a low of $837000.0 in Q1 2024.
• A 5-year average of $12.1 million and a median of $1.7 million in 2024 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net plunged 98.12% in 2024 and soared 93.91% in 2025, its largest moves.
• Tracing VYGR's Receivables - Net over 5 years: stood at $10.0 million in 2022, then surged by 701.5% to $80.1 million in 2023, then sank by 98.12% to $1.5 million in 2024, then rose by 17.09% to $1.8 million in 2025, then fell by 15.16% to $1.5 million in 2026.
• Business Quant data shows VYGR's Receivables - Net at $1.5 million in Q1 2026, $1.8 million in Q4 2025, and $3.2 million in Q3 2025.